Company intelligence / Profile preview

Dexo BioPharm

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

Dexo Bio is a South Korean biotechnology company specializing in the development of engineered exosome therapeutics. The company's proprietary platform focuses on the isolation, purification, and modification of exosomes to deliver therapeutic proteins or nucleic acids to specific target cells. Their current pipeline includes programs for solid tumors, atopic dermatitis, and non-alcoholic steatohepatitis (NASH). Dexo Bio aims to address the limitations of current drug delivery systems by utilizing the natural biocompatibility and low immunogenicity of exosomes.

Therapeutic areas: OncologyDermatologyGastroenterology
Modalities: Exosome-based therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Dexo BioPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dexo BioPharm.

Explore the full profile